IMPAACT P1066: A PHASE I/II MULTICENTER, OPEN-LABEL, NONCOMPARATIVE STUDY OF

IMPAACT P1066：I/II 期多中心、开放标签、非比较研究

• 批准号: 8167353
• 负责人: Steven L. Zeichner
• 金额: $ 2.19万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-20 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167353
• 关键词: Adolescent; Child; Computer Retrieval of Information on Scientific Projects Database; Drug Kinetics; Funding; Grant; HIV-1; IMPAACT; Institution; Phase; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; aged; open label

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and efficacy or raltegravir in HIV-1 infected children and adolescents, aged 2-19 years.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究的目的是评估拉替拉韦对 2-19 岁 HIV-1 感染儿童和青少年的安全性、耐受性、药代动力学和疗效。